AI Drug Lowers Six Biological Age Clocks in Phase IIa
A Phase IIa trial published in Nature Biotechnology found that rentosertib — an AI-designed TNIK kinase inhibitor — measurably modulated aging biomarkers across six validated proteomic clocks measuring over 2,800 blood proteins. The study offers the first human evidence that a single drug can decelerate multiple independent proteomic aging signatures simultaneously.
- Rentosertib is a TNIK inhibitor originally designed by AI modelling
- 2,800+ blood proteins measured across six proteomic aging clocks
- Phase IIa design; larger replication trials are required